May 17, 2020

Pernix Therapeutics to buy Somaxon for $25 mln

stock-for-stock deal
California-based company
growth strat
Admin
2 min
Pernix Therapeutics to buy Somaxon for $25 mln
Speciality pharmaceutical company Pernix Therapeutics Holdings, Inc said it has signed a merger deal with Somaxon Pharmaceuticals, Inc to acquire Somax...

Speciality pharmaceutical company Pernix Therapeutics Holdings, Inc said it has signed a merger deal with Somaxon Pharmaceuticals, Inc to acquire Somaxon in a stock-for-stock deal for $25 million.

As per the terms of the deal, California-based Somaxon stockholders will receive aggregate consideration worth $25 million in Pernix common stock.

The number of shares of Pernix common stock to be issued to the stockholders of Somaxon will be based on the volume-weighted average price of Pernix’s common stock over the 30 day period ending on the day immediately prior to the closing of the merger.  

CEO and President of Pernix, Cooper Collins said, “The acquisition of Somaxon is another step in the growth strategy of Pernix which is likely to continue to expand our product portfolio, in addition to our recently announced agreements to buy Cypress Pharmaceuticals and Hawthorn Pharmaceuticals. Somaxon’s product Silenor, which is a non-seasonal product, broadens our product line and may also have potential as an OTC product in the future.” 

Silenor is approved to treat insomnia characterized by difficulty with sleep maintenance and is not a controlled substance.

The pharmaceutical company Pernix expects the net sales from Silenor on an annualized basis to be in the range of around $10 million to $15 million and EBIDTA resulting from such Silenor net sales in the range of approximately $5 million to $10 million.

Richard W Pascoe, Somaxon's President and Chief Executive Officer, said, "We believe this acquisition will provide the opportunity to more fully capitalize on the Silenor brand. Moreover, with Pernix's recently announced acquisition of Cypress and Hawthorn, we believe that the combined entity, with its broad platform of branded, generic and OTC products, represents long-term value for the benefit of all of our stockholders. We look forward to working with the Pernix management team as we integrate Somaxon with Pernix."

Pernix Pharmaceuticals is focused on sales, marketing, manufacturing and development of branded, generic and OTC pharmaceutical products. Somaxon Pharmaceuticals is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded products. 

Share article

Jun 17, 2021

Dexcom: changing the lives of people with type 1 diabetes

diabetes
glucosemonitoring
type1diabetes
insulin
3 min
British actress Nina Wadia OBE tells us how her son's life has changed since using glucose monitoring system Dexcom

It is estimated that 9.3% of adults around the world are living with type 1 diabetes, which amounts to a total of 463 million people. A further 1.1 million children and adolescents under the age of 20 are living with the condition. 

Unlike the more prevalent type 2 diabetes, where the body still produces insulin and symptoms develop slowly, people with type 1 diabetes need regular insulin injections or pumps, and must monitor their sugar levels frequently. 

In recent years a number of remote glucose monitoring systems have become available that patients can use at home. These work with a sensor, usually placed under the skin, that measures glucose levels every few minutes. This information is then transmitted wirelessly to a device like a smartphone or tablet, which can then be shared with their clinician. 

British actress Nina Wadia's son Aidan, 14, has type 1 diabetes, and has been managing his condition using Dexcom, a glucose monitoring system used by patients all over the world. Here Wadia explains how Dexcom has improved their lives. 

As a parent of someone with type 1 diabetes, what is your day-to-day life like?
Being able to take a breath, think and pivot constantly without getting frustrated becomes an essential mindset because sometimes it feels like each day is determined to be different from the day before. Whatever worked yesterday is going to misfire today. 

Which areas of yours and Aidan’s life are most impacted by diabetes? 
The one thing that you have to fight hard to reclaim is spontaneity, especially when it comes to food and exercise. It’s only when this is taken do you realise how essential each one is. You can be flexible and there are no real limits, but only in the sense that a great athlete can be flexible without limits because they’ve trained super hard to be that way. So we’ve all had to become athletes when it comes to being spontaneous.

How has Dexcom helped you and Aidan? 
Dexcom has brought future science fiction to real life today. The continuous glucose monitoring system is tiny, sits discreetly on his body and gives him a ten-day breather between sensor changes, so it's goodbye finger-pricking seven times daily. 

Dexcom is totally active at a grass roots level and for Diabetes Awareness has pledged to donate £2,000 if #DexcomDiabetesStories and/or #DexcomWarriorStories is shared 200 times! I’ll be sharing more on social media and would love to hear how other families are winning their fights.

Maybe most importantly Dexcom is trying to introduce a reimbursement programme for type 1 diabetes  patients which will give greater access to modern, life changing hi-tech. I want to spread the word on the importance of accessing it through this campaign. 

If you compared your life today with how it was before Aidan was using Dexcom, what has changed? 
It's always working, which lets him take his mind off diabetes for longer stretches. It also lets me get off his back. We both receive alerts so I no longer have to pester him by asking him what his number is, and especially importantly, I don’t have to wake him at night to prick his finger if I’m worried. Dexcom gave us back our sleep!

Share article